Equities analysts expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report sales of $25.30 million for the current quarter, according to Zacks. Five analysts have issued estimates for BioDelivery Sciences International’s earnings, with the highest sales estimate coming in at $27.30 million and the lowest estimate coming in at $24.46 million. BioDelivery Sciences International posted sales of $12.18 million in the same quarter last year, which suggests a positive year over year growth rate of 107.7%. The company is scheduled to report its next earnings results on Thursday, August 8th.
On average, analysts expect that BioDelivery Sciences International will report full-year sales of $102.50 million for the current financial year, with estimates ranging from $99.90 million to $107.25 million. For the next year, analysts anticipate that the firm will report sales of $147.30 million, with estimates ranging from $135.60 million to $155.87 million. Zacks’ sales calculations are an average based on a survey of research firms that cover BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. The company had revenue of $19.77 million during the quarter, compared to analyst estimates of $19.60 million.
A number of research analysts have issued reports on BDSI shares. Zacks Investment Research lowered HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Cantor Fitzgerald set a $8.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, May 10th. Finally, BidaskClub lowered Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $6.20.
BDSI stock traded up $0.04 during trading on Friday, reaching $3.81. 829,500 shares of the company’s stock were exchanged, compared to its average volume of 988,305. The company has a current ratio of 2.88, a quick ratio of 2.57 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 1-year low of $2.35 and a 1-year high of $5.37. The company has a fifty day simple moving average of $4.35. The stock has a market capitalization of $337.45 million, a price-to-earnings ratio of -5.22 and a beta of 0.47.
In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $4.68, for a total value of $37,440.00. Following the sale, the director now owns 604,754 shares of the company’s stock, valued at approximately $2,830,248.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Healthcare Master Fun Broadfin sold 1,800,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $5.00, for a total value of $9,000,000.00. The disclosure for this sale can be found here. Insiders sold a total of 2,429,743 shares of company stock worth $11,707,558 in the last three months. Company insiders own 8.94% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC raised its stake in shares of BioDelivery Sciences International by 942.8% in the 4th quarter. Barclays PLC now owns 328,039 shares of the specialty pharmaceutical company’s stock worth $1,214,000 after buying an additional 296,582 shares in the last quarter. Close Asset Management Ltd raised its position in shares of BioDelivery Sciences International by 1,340.0% during the first quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock worth $95,000 after purchasing an additional 16,750 shares during the period. 1492 Capital Management LLC raised its position in shares of BioDelivery Sciences International by 175.1% during the fourth quarter. 1492 Capital Management LLC now owns 881,788 shares of the specialty pharmaceutical company’s stock worth $3,263,000 after purchasing an additional 561,265 shares during the period. Pura Vida Investments LLC acquired a new stake in shares of BioDelivery Sciences International during the fourth quarter worth $2,305,000. Finally, Nantahala Capital Management LLC raised its position in shares of BioDelivery Sciences International by 64.0% during the fourth quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock worth $10,114,000 after purchasing an additional 1,066,900 shares during the period. 56.72% of the stock is currently owned by institutional investors.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.